New insider activity at Chemed ( (CHE) ) has taken place on September 10, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Patrick Grace recently sold 150 shares of Chemed stock, amounting to a total transaction value of $69,508.
Recent Updates on CHE stock
In the past 24 hours, Chemed’s stock has seen mixed analyst actions with notable changes in price targets. BofA lowered its price target due to concerns over a potentially negative policy and reimbursement environment, despite solid hospital fundamentals. Meanwhile, Jefferies upgraded Chemed to a Buy, citing favorable fiscal 2026 reimbursement rates, particularly in Florida, which are expected to boost the company’s EBITDA. Additionally, aggressive share buybacks are anticipated to drive the stock’s multiple higher. Oppenheimer also adjusted its price target downward, reflecting broader market considerations. These developments highlight a blend of cautious optimism and strategic financial maneuvers influencing Chemed’s stock outlook.
Spark’s Take on CHE Stock
According to Spark, TipRanks’ AI Analyst, CHE is a Outperform.
Chemed’s overall stock score reflects its strong financial performance and stable valuation, which are offset by technical indicators suggesting potential bearish momentum and challenges highlighted in the earnings call and corporate events. The lowered earnings guidance further impacts the outlook, contributing to a cautious sentiment.
To see Spark’s full report on CHE stock, click here.
More about Chemed
YTD Price Performance: -12.38%
Average Trading Volume: 182,430
Technical Sentiment Signal: Sell
Current Market Cap: $6.76B